NCT01956734View on ClinicalTrials.gov

Virus DNX2401 and Temozolomide in Recurrent Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2017

Conditions
Glioblastoma MultiformeRecurrent Tumor
Interventions
PROCEDURE

DNX2401 and Temozolomide

"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection."

Trial Locations (1)

31008

Clinica Universidad de Navarra, Pamplona

Sponsors

Collaborators (1)

DNAtrix, Inc.
All Listed Sponsors
collaborator

DNAtrix, Inc.

INDUSTRY

lead

Clinica Universidad de Navarra, Universidad de Navarra

OTHER

NCT01956734 - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter